Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 18/20 | 0.64 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | CCL2 | P13500 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29848195 | 0.78 | BRD4 (1.00) | BRD4 | |
| SCHEMBL16652223 | 0.78 | BRD4 (1.00) | BRD4 | |
| SCHEMBL21508055 | 0.75 | OPRD1 (0.47) | BRD4 | |
| SCHEMBL21921488 | 0.74 | MAOB (0.40) | BRD4 | |
| SCHEMBL8231701 | 0.74 | HTR7 (0.41) | BRD4 | |
| SCHEMBL16650964 | 0.73 | BRD4 (1.00) | BRD4 | |
| SCHEMBL29848826 | 0.73 | BRD4 (1.00) | BRD4 | |
| SCHEMBL4159024 | 0.73 | BRD4 (0.55) | BRD4PTGDR2NR1H2NR1H3 | |
| SCHEMBL11575773 | 0.72 | KDM4E (0.54) | BRD4 | |
| SCHEMBL16651428 | 0.72 | BRD4 (0.61) | BRD4CCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562915-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20180273547-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2018-09-27 | — | — | US | disclosed |
| US-9288869-B2 | Styryl-based compound, composition containing styryl-based compound, and organic light emitting diode including styryl-based compound | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562915-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | BRD4 5/4885PTGDR2 2846/4885CCL2 2524/4885 |
| US-20180273547-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | BRD4 5/4885PTGDR2 2846/4885CCL2 2524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.